-
1
-
-
84983373947
-
-
[homepage on the Internet], melanoma version 3.2015. NCCN; 2015, Accessed February 3
-
®): melanoma version 3.2015. NCCN; 2015. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed February 3, 2016.
-
(2016)
®)
-
-
-
3
-
-
84870878674
-
Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist: Part II: Management of stage IV disease
-
Fox MC, Lao CD, Schwartz JL, et al. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: management of stage IV disease. J Am Acad Dermatol. 2013;68(1):13.e1–13.
-
(2013)
J am Acad Dermatol
, vol.68
, Issue.1
, pp. 13.e1-13.e13
-
-
Fox, M.C.1
Lao, C.D.2
Schwartz, J.L.3
-
4
-
-
84886895936
-
-
[homepage on the Internet], WHO, Accessed February 3
-
World Health Organization [homepage on the Internet]. Ultraviolet radiation and the INTERSUN Programme. WHO; 2012. Available from: http://www.who.int/uv/en/. Accessed February 3, 2016.
-
(2012)
Ultraviolet Radiation and the INTERSUN Programme
-
-
-
5
-
-
84866600895
-
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Dummer R, Hauschild A, Guggenheim M, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii86–vii91.
-
(2012)
Ann Oncol
, vol.23
, pp. vii86-vii91
-
-
Dummer, R.1
Hauschild, A.2
Guggenheim, M.3
-
6
-
-
84934897714
-
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
-
Niezgoda A, Niezgoda P, Czajkowski R. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int. 2015;2015:851387.
-
(2015)
Biomed Res Int
, vol.2015
-
-
Niezgoda, A.1
Niezgoda, P.2
Czajkowski, R.3
-
7
-
-
84901640582
-
Recent developments in the medical and surgical treatment of melanoma
-
Saranga-Perry V, Ambe C, Zager JS, Kudchadkar RR. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin. 2014;64(3):171–185.
-
(2014)
CA Cancer J Clin
, vol.64
, Issue.3
, pp. 171-185
-
-
Saranga-Perry, V.1
Ambe, C.2
Zager, J.S.3
Kudchadkar, R.R.4
-
8
-
-
84929223574
-
Immunologic correlates in the course of treatment with immunomodulating antibodies
-
Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L. Immunologic correlates in the course of treatment with immunomodulating antibodies. Semin Oncol. 2015;42(3):448–458.
-
(2015)
Semin Oncol
, vol.42
, Issue.3
, pp. 448-458
-
-
Weide, B.1
Di Giacomo, A.M.2
Fonsatti, E.3
Zitvogel, L.4
-
9
-
-
84924272311
-
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
-
Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–3492.
-
(2015)
Oncotarget
, vol.6
, Issue.6
, pp. 3479-3492
-
-
Luke, J.J.1
Ott, P.A.2
-
10
-
-
84919682995
-
Immuno-oncology combinations: A review of clinical experience and future prospects
-
Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res. 2014;20(24):6258–6268.
-
(2014)
Clin Cancer Res
, vol.20
, Issue.24
, pp. 6258-6268
-
-
Antonia, S.J.1
Larkin, J.2
Ascierto, P.A.3
-
11
-
-
84922004360
-
Clinical impact of checkpoint inhibitors as novel cancer therapies
-
Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs. 2014;74(17):1993–2013.
-
(2014)
Drugs
, vol.74
, Issue.17
, pp. 1993-2013
-
-
Shih, K.1
Arkenau, H.T.2
Infante, J.R.3
-
12
-
-
84939967609
-
The role of anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
-
Tsai KK, Daud AI. The role of anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs. 2015;75(6):563–575.
-
(2015)
Drugs
, vol.75
, Issue.6
, pp. 563-575
-
-
Tsai, K.K.1
Daud, A.I.2
-
13
-
-
84896714827
-
Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study
-
McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–332.
-
(2014)
Lancet Oncol
, vol.15
, Issue.3
, pp. 323-332
-
-
McArthur, G.A.1
Chapman, P.B.2
Robert, C.3
-
14
-
-
84863673204
-
Improved survival with MEK inhibition in BRAF-mutated melanoma
-
Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
-
(2012)
N Engl J Med
, vol.367
, Issue.2
, pp. 107-114
-
-
Flaherty, K.T.1
Robert, C.2
Hersey, P.3
-
15
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
-
(2012)
Lancet
, vol.380
, Issue.9839
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
16
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714.
-
(2012)
N Engl J Med
, vol.366
, Issue.8
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
-
17
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
18
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O’Day, S.J.2
McDermott, D.F.3
-
19
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
20
-
-
84920031180
-
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates
-
Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856.
-
(2014)
Cancer Immunol Res
, vol.2
, Issue.9
, pp. 846-856
-
-
Wang, C.1
Thudium, K.B.2
Han, M.3
-
21
-
-
84929156397
-
Toxicity patterns with immunomodulating antibodies and their combinations
-
Haanen JB, Thienen HV, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015;42(3):423–428.
-
(2015)
Semin Oncol
, vol.42
, Issue.3
, pp. 423-428
-
-
Haanen, J.B.1
Thienen, H.V.2
Blank, C.U.3
-
22
-
-
84898973055
-
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
-
Topalian SL, Mario S, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
-
(2014)
J Clin Oncol
, vol.32
, Issue.10
, pp. 1020-1030
-
-
Topalian, S.L.1
Mario, S.2
McDermott, D.F.3
-
23
-
-
84859158384
-
Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity
-
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207–212.
-
(2012)
Curr Opin Immunol
, vol.24
, Issue.2
, pp. 207-212
-
-
Topalian, S.L.1
Drake, C.G.2
Pardoll, D.M.3
-
24
-
-
84936147067
-
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34.
-
(2015)
N Engl J Med
, vol.373
, Issue.1
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
-
25
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017.
-
(2015)
N Engl J Med
, vol.372
, Issue.21
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
-
26
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
-
(2015)
N Engl J Med
, vol.372
, Issue.4
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
-
27
-
-
84931083080
-
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial
-
Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384.
-
(2015)
Lancet Oncol
, vol.16
, Issue.4
, pp. 375-384
-
-
Weber, J.S.1
D’Angelo, S.P.2
Minor, D.3
-
28
-
-
0033610734
-
Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement
-
Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999;354(9193):1896–1900.
-
(1999)
Lancet
, vol.354
, Issue.9193
, pp. 1896-1900
-
-
Moher, D.1
Cook, D.J.2
Eastwood, S.3
-
30
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
-
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
-
(2009)
Eur J Cancer
, vol.45
, Issue.2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
31
-
-
84996528887
-
Treatment options expanding for advanced melanoma
-
Thompson JA. Treatment options expanding for advanced melanoma. J Natl Compr Canc Netw. 2015;13(5 Suppl):673–675.
-
(2015)
J Natl Compr Canc Netw
, vol.13
, Issue.5
, pp. 673-675
-
-
Thompson, J.A.1
-
32
-
-
84929178180
-
The ipilimumab lesson in melanoma: Achieving long-term survival
-
Delyon J, Maio M, Lebbé C. The ipilimumab lesson in melanoma: achieving long-term survival. Semin Oncol. 2015;42(3):387–401.
-
(2015)
Semin Oncol
, vol.42
, Issue.3
, pp. 387-401
-
-
Delyon, J.1
Maio, M.2
Lebbé, C.3
-
33
-
-
84878432797
-
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival
-
Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24(6):1697–1703.
-
(2013)
Ann Oncol
, vol.24
, Issue.6
, pp. 1697-1703
-
-
Delyon, J.1
Mateus, C.2
Lefeuvre, D.3
-
34
-
-
84901246811
-
Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort
-
Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12(1):116.
-
(2014)
J Transl Med
, vol.12
, Issue.1
-
-
Ascierto, P.A.1
Simeone, E.2
Sileni, V.C.3
-
35
-
-
84876678621
-
Patterns of onset and resolution of immune–related adverse events of special interest with ipilimumab
-
Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune–related adverse events of special interest with ipilimumab. Cancer. 2013;119(9):1675–1682.
-
(2013)
Cancer
, vol.119
, Issue.9
, pp. 1675-1682
-
-
Weber, J.S.1
Dummer, R.2
De Pril, V.3
|